Pulmonary Hypertension – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of PH for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the remaining countries covered in this report.
Clarivate Epidemiology’s PH forecast will answer the following questions:
- Of all people diagnosed PH, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PH over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following PH patient populations:
- Diagnosed prevalent cases of PH.
- Diagnosed prevalent cases of PH by subtype.
- Diagnosed prevalent cases of PAH by etiology.
- Diagnosed prevalent cases of PAH by New York Heart Association (NYHA) severity classification scheme.
- Diagnosed prevalent cases of PH associated with left-heart disease (LHD).
- Diagnosed prevalent cases of PH associated with LHD by etiology subtype.
- Diagnosed prevalent cases of PH associated with chronic lung disease.
- Diagnosed prevalent cases of PH associated with chronic lung disease by comorbid lung condition.
- Diagnosed prevalent cases of chronic thromboembolic pulmonary hypertension (CTEPH).
- Diagnosed prevalent cases of CTEPH by surgical intervention.
- Diagnosed prevalent cases of PH caused by miscellaneous factors.
- Diagnosed prevalent cases of PH by drug treatment.
Note: Coverage may vary by country and region.
Table of contents
- Pulmonary Hypertension - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in / excluded from the analyses of pulmonary hypertension)
- Diagnosed prevalence of pulmonary hypertension
- Diagnosed prevalence of pulmonary hypertension by etiology
- Diagnosed prevalence of pulmonary arterial hypertension by etiology
- Diagnosed prevalence of pulmonary arterial hypertension by New York Heart Association functional classification scheme
- Diagnosed prevalence of pulmonary hypertension due to left heart disease by subgroup
- Diagnosed prevalence of pulmonary hypertension due to chronic lung disease by comorbid lung condition
- Diagnosed prevalence of inoperable chronic thromboembolic pulmonary hypertension
- Diagnosed prevalence of chronic thromboembolic pulmonary hypertension by surgical intervention
- Drug-treated prevalent cases
- Risk / protective factors applied to disease forecast models
- Reference Materials
